Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $75
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $66 to $75.
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $66 to $75.